A simple procedure to eliminate the interference from keto-opiates in the analysis of 6-monoacetylmorphine (6-MAM) by gas chromatography-mass spectrometry is described. The prelreatment of urine samples with sodium bisulfite followed by solld.phase extraction results in the elimination of the bisulfite addition products formed from the reaction of the bisulfite ions with the carbonyl carbon of the keto-opiates. This simple procedure results in the accurate quantitation of 6-MAM at a concentration of 4 ng/mL in the presence of keto-opiates up to 10,000 ng/mL.
Introduction
The recent changes in the Federal Guidelines for workplace drug testing (1) has brought into prominence the role of 6-monoacetylmorphine (6-MAM) testing. There is a requirement for certified laboratories to be able to test for 6-MAM at a cutoff concentration of 10 ng/mL for routine samples that test positive for morphine at a concentration of 2000 ng/rnL or greater. There is a further requirement that certified laboratories must be able to detect and accurately quantitate 6-MAM i~ retest samples at a concentration of 40% of the cutoff. This requirement of the limit of quantitation of at least 4 ng/mL, certainly challenges certified laboratories to have robust methods for the analysis of 6-HAM.
There are a number of gas chromatography-mass spectrometry (GC-MS) methods available for the analysis of 6-HAM (2) (3) (4) . Methods that use the trimethylsilyl derivative are COmmon for the analysis of 6-MAM. Although these methods produce stable derivatives of 6-MAM, our experience shows that keto-opiates such as hydrocodone, hydromorphone, oxycodone, and oxymorphone can create problems with the quantitation of 6-HAM because of the coelution of the trimethylsilyl * Author to whom correspondence should be addressed.
derivatives of these compounds with the 6-MAM derivative.
Described here is a simple procedure to overcome the interferences of the keto-opiates on the analysis of 6-MAM. The pretreatment of urine samples with sodium bisulfite results in the formation of bisulfite addition products, which is caused by the nucieophiiic attack of the bisulfite ion on the carbonyt carbon of the keto-opiates (5). The pretreated urine is then subjected to solid-phase extraction (SPE) procedures followed by derivatization with N,O-bis-(trimethylsilyl)trifluoroacetamide (BSTFA) to form the trimethylsilyl derivatives of the 6-MAM. This protocol enables the accurate quantitation of 6-MAM in urine samples that may contain the individual or combination of keto-opiates at concentrations as high as 10,000 ng/mL.
Materials and Methods
Sodium Bisulfite (99% or greater purity) was purchased from Sigma, (St. Louis, Mo). World Wide Monitoring Clean Screen SPE columns were purchased from United Chemical Technologies, (Bristol, PA). 6-MAM and 6-MAM-d3 were purchased from Radian Corp. (Austin, TX). Pure drug standards were purchased from Alltech (State College, PA). All solvents and reagents were analytical or HPLC grade.
Analysis of 6-MAM by GC-MS
Urine aliquots (5 rnL) were spiked with the internal standard (6-MAM-d3) and extracted using the World Wide Monitoring Clean Screen SPE columns as described in the application manual provided by the manufacturer (6) . The eluate from the column was dried under a gentle stream of nitrogen and then derivatized with 50 pL of BSTFA (with 1% TMCS). Derivatized aliquots (1 pL) were analyzed on a Hewlett-Packard model 6890 gas chromatograph (GC) equipped with a 5973 mass spectrometer. A DB-5 column (15 m x 0.25-ram i.d., 0.25-pro film thickness, J&W Scientific, Folsorn, CA) was used for the chromatography. The initial oven temperature was 100~ and was held for t min followed by a ramp at 25~ to 230~ This was held for 1 min followed by a second ramp at 3~ to a final temperature of 260~ Selected ion monitoring mode was used to quantitate 6-MAM. The ions monitored were 399 (quantitating ion), 400, and 340. For the internal standard, 6-MAM-d~, the ions 402 (quantitating) and 343 were monitored. All quantitative calculations were performed automatically by the Target 3.2 data analysis software (Thru-Put Systems, Inc., Orlando, FL) on the GC-MS system. The assay was calibrated using four calibrators that were extracted with each batch of samples. The calibrators were prepared by spiking pure drug into negative urine at 4, 10, 20, and 40 ng/mL.
Bisulfite pretreatment
Urine samples (5-mL aliquots), calibrators, and controls were spiked with internal standard (6-MAM-d3). To each tube was added 1.5 mL of a saturated solution of sodium bisulfite. The tubes were incubated at room temperature for 15 min.
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Results

Effect of keto-opiates and the elimination of interference on 6-MAM analysis
The effect of 5000 ng/mL of three different keto-opiates (hydromorphone, oxycodone, and ox ~,morphone) spiked into a urine sample containing 4 ng/mL of 6-MAM is shown in Figures 1-3 , respective]y. In the presence of hydromorphone and oxycodone ( Figures 1A and 2A) , the chromatography of 6-MAM is significantly compromised. With the pretreatment of the samples with bisuifite, the hydromorphone and oxycodone interference on 6-MAM is eliminated (Figures 1B and   2B) . Oxymorphone does not interfere with the analysis of 6-MAM in our assay (Figure 3.4,) , but there is a massive peak of mass 399 that elutes before the 6-MAM peak. This diminishes the size of peak of the analyte of interest as the y-axis in the ion window is scaled automatically to the highest peak. Although this is not a problem, as the width of the display window can be altered, pretreatment of the sample with sodium bisulfite (Figure 3B ) significantly reduced the amount of this interfering peak and the amount of material that is deposited on the gas chromatography (GC) column.
The interference from hydrocodone on 6-MAM is minimal. The analysis of a similar sample to that described in Figures  1-3 , produced a quantitative value for 6-MAM of 4.0 ng/mL in the presence of 5000 ng/mL of hydrocodone. However, the resolution of the 6-MAM quantitating ion (mass 399) and the qualifying ion (mass 400) exceeded the criteria of 10% resolution of the analyte ion peak height to the baseline from any adjacent peaks. The pretreatment with sodium bisulfite eliminated a large peak that eluted just before the 6-MAM peak, thereby improving the resolution.
Experiments were also performed by spiking a combination of hydrocodone and hydromorphone, oxycodone, or oxymorphone at a concentration of 5000 ng/mL each into urine sampies containing 4 ng/mL of 6-MAM. Pretreatment of these sampies with sodium bisulfite was effective in eliminating the combined effect of the two keto-opiates in each sample. The recovery of 6-MAM in each sample was within 80% of the target concentration of 4 ng/mL.
The ability to eliminate the interference is dependent on the amount of bisulfite that is added to the sample. If the concentration of the keto-opiates is doubled to 10,000 ng/mL, increasing the amount of bisulfite to 2 mL per 5-mL aliquot of urine is necessary. With this increase in bisulfite, recovery of 6-MAM to within + 20% of the target 6-MAM concentration of 4 ng/mL was obtained in samples that were spiked with 10,000 ng/mL of each of the 4 keto-opiates in urine samples that contained 4 ng/mL of 6-MAM. 
Discussion
The pretreatment of urine samples with chemicals to eliminate the interference by certain drugs on GC-MS confirmation assays is not uncommon. For example, in the GC-MS assay for the confirmation of amphetamine and methamphetamine, pretreatment of the urine samples by sodium periodate eliminates the interference caused by the presence of high concentrations of ephedrine and other ~-hydroxyamines (7). Recent reports have shown that the interference by keto-opiates on the GC-MS assay for morphine and codeine can be eliminated by the pretreatment of urine samples with hydroxylamine hydrochloride to form oximes of the keto groups of these opiates (8,9).
Bisulfite addition products are used in organic chemistry to separate carbonyl compounds from noncarbonyl compounds. This concept has been extended to the forensic drug testing laboratory. Bisulfite addition products, being water soluble, are removed during the SPE of the urine samples after the reJournal of Analytical Toxicology, Vol. 24, January/February 2000 action with sodium bisulfite. This simple technique of incorporating a pretreatment step with sodium bisulfite in the 6-MAM procedure eliminates the interference from high concentrations of keto-opiates with the trimethylsilyl derivatives of 6-MAM.
